| Title： | Practice guide of drug monitoring and management for the treatment of inflammatory bowel disease in children in China（2023） |
| Edition： | Original |
| Classification： | Experts consensus |
| Field： | Diagnosis and Treatment |
| Countries and regions： | China |
| Guidelines users： | pediatrician |
| Evidence classification method： | 德尔菲法 |
| Development unit： | Shengjing Hospital of China Medical University |
| Registration time: | 2023-09-20 |
| Registration number： | PREPARE-2023CN403 |
| Purpose of the guideline: | To provide unified standards and standardized recommendations for the monitoring of therapeutic drugs for children with inflammatory bowel disease in China |
